Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Orchestra BioMed Holdings, Inc. reported revenue of $33M, up 1169.2% year over year. Operating margin was -154.7% and net margin -157.4%, on a free-cash-flow margin of -147.7% with capital expenditure at 1.5% of revenue. Every figure is computed directly from OBIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $33M | -154.7% | -157.4% |
| FY2024 | $3M | -2437.5% | -2313.3% |
| FY2023 | $3M | -1866.2% | -1779.7% |
| FY2022 | $4M | -924.3% | -951.3% |
| FY2021 | n/a | n/a | n/a |
How does OBIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.